Liposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT07689162
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Pain, Postoperative

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Standard Bupivacaine — DRUG
    Volume: 4 mL of 0.75% bupivacaine hydrochloride
  • Liposomal Bupivacaine — DRUG
    Volume: 1.5 mL of 0.75% bupivacaine hydrochloride and 2.5 mL of liposomal bupivacaine

Study Details

The purpose of this study is to find out which pain medication is more effective in reducing pain after nose surgery (rhinoplasty). The investigators are looking to find the best treatment to reduce discomfort and improve the healing process for patients having nose surgery.

Key Dates

First listed
Jul 8, 2026
Start date
Aug 1, 2026
Status verified
Aug 2026
Primary completion
Jun 30, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
45 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liposomal Bupivacaine
    Participants randomized to the experimental arm will receive bilateral supraorbital and infraorbital nerve blocks using liposomal bupivacaine at the end of surgery.
  • Active Comparator: Standard Bupivacaine
    The control arm will receive standard bupivacaine nerve blocks using the same injection sites and volumes appropriate for safe regional anesthesia

Primary Outcome Measure

Cumulative opioid consumption [ Time Frame: First 72 hours postoperatively ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Washington UniversitySt LouisMissouri63110
Sara Kukuljan, BS, RN
[email protected]
314-362-7563

Find similar trials in St Louis, MO

By research site
Washington University· St Louis, MO

Related Studies